Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. (RIGL) Stock Competitors & Peer Comparison
See (RIGL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RIGL | $29.37 | +12.10% | 543.4M | 1.52 | $19.29 | N/A |
| VRTX | $448.29 | +3.01% | 113.8B | 26.60 | $16.85 | N/A |
| REGN | $723.41 | +1.49% | 74.5B | 17.66 | $40.96 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $812.81 | -0.06% | 50.3B | 36.06 | $22.54 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $292.03 | +2.52% | 39B | 73.16 | $3.99 | N/A |
| RVMD | $145.72 | +1.09% | 31B | -20.50 | -$7.11 | N/A |
| INSM | $116.00 | +11.66% | 25.1B | -20.14 | -$5.76 | N/A |
| UTHR | $581.74 | +2.08% | 24.7B | 21.50 | $27.06 | N/A |
Stock Comparison
RIGL vs VRTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, VRTX has a market cap of 113.8B. Regarding current trading prices, RIGL is priced at $29.37, while VRTX trades at $448.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas VRTX's P/E ratio is 26.60. In terms of profitability, RIGL's ROE is +1.47%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RIGL is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check VRTX's competition here
RIGL vs REGN Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, REGN has a market cap of 74.5B. Regarding current trading prices, RIGL is priced at $29.37, while REGN trades at $723.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas REGN's P/E ratio is 17.66. In terms of profitability, RIGL's ROE is +1.47%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RIGL is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check REGN's competition here
RIGL vs VRNA Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RIGL is priced at $29.37, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RIGL's ROE is +1.47%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, RIGL is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check VRNA's competition here
RIGL vs ARGX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ARGX has a market cap of 50.3B. Regarding current trading prices, RIGL is priced at $29.37, while ARGX trades at $812.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ARGX's P/E ratio is 36.06. In terms of profitability, RIGL's ROE is +1.47%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, RIGL is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ARGX's competition here
RIGL vs SGEN Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RIGL is priced at $29.37, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RIGL's ROE is +1.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RIGL is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check SGEN's competition here
RIGL vs ALNY Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ALNY has a market cap of 39B. Regarding current trading prices, RIGL is priced at $29.37, while ALNY trades at $292.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ALNY's P/E ratio is 73.16. In terms of profitability, RIGL's ROE is +1.47%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RIGL is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ALNY's competition here
RIGL vs RVMD Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, RVMD has a market cap of 31B. Regarding current trading prices, RIGL is priced at $29.37, while RVMD trades at $145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas RVMD's P/E ratio is -20.50. In terms of profitability, RIGL's ROE is +1.47%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RIGL is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check RVMD's competition here
RIGL vs INSM Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, RIGL is priced at $29.37, while INSM trades at $116.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas INSM's P/E ratio is -20.14. In terms of profitability, RIGL's ROE is +1.47%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RIGL is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RIGL.Check INSM's competition here
RIGL vs UTHR Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, UTHR has a market cap of 24.7B. Regarding current trading prices, RIGL is priced at $29.37, while UTHR trades at $581.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas UTHR's P/E ratio is 21.50. In terms of profitability, RIGL's ROE is +1.47%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RIGL is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check UTHR's competition here
RIGL vs BNTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, BNTX has a market cap of 23.7B. Regarding current trading prices, RIGL is priced at $29.37, while BNTX trades at $93.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas BNTX's P/E ratio is -15.71. In terms of profitability, RIGL's ROE is +1.47%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RIGL is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check BNTX's competition here
RIGL vs RPRX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, RPRX has a market cap of 22.2B. Regarding current trading prices, RIGL is priced at $29.37, while RPRX trades at $51.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas RPRX's P/E ratio is 27.21. In terms of profitability, RIGL's ROE is +1.47%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, RIGL is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check RPRX's competition here
RIGL vs MRNA Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, MRNA has a market cap of 21.1B. Regarding current trading prices, RIGL is priced at $29.37, while MRNA trades at $53.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas MRNA's P/E ratio is -6.54. In terms of profitability, RIGL's ROE is +1.47%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RIGL is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check MRNA's competition here
RIGL vs ROIV Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ROIV has a market cap of 21B. Regarding current trading prices, RIGL is priced at $29.37, while ROIV trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ROIV's P/E ratio is -25.12. In terms of profitability, RIGL's ROE is +1.47%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, RIGL is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ROIV's competition here
RIGL vs BGNE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RIGL is priced at $29.37, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RIGL's ROE is +1.47%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RIGL is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check BGNE's competition here
RIGL vs INCY Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, INCY has a market cap of 19.8B. Regarding current trading prices, RIGL is priced at $29.37, while INCY trades at $99.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas INCY's P/E ratio is 14.00. In terms of profitability, RIGL's ROE is +1.47%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RIGL is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check INCY's competition here
RIGL vs DNA-WT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RIGL is priced at $29.37, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RIGL's ROE is +1.47%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RIGL is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check DNA-WT's competition here
RIGL vs GMAB Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, GMAB has a market cap of 16.6B. Regarding current trading prices, RIGL is priced at $29.37, while GMAB trades at $27.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas GMAB's P/E ratio is 20.52. In terms of profitability, RIGL's ROE is +1.47%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, RIGL is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check GMAB's competition here
RIGL vs SMMT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, RIGL is priced at $29.37, while SMMT trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas SMMT's P/E ratio is -11.92. In terms of profitability, RIGL's ROE is +1.47%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RIGL is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check SMMT's competition here
RIGL vs ASND Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, RIGL is priced at $29.37, while ASND trades at $237.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ASND's P/E ratio is 26.61. In terms of profitability, RIGL's ROE is +1.47%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RIGL is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ASND's competition here
RIGL vs JAZZ Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, JAZZ has a market cap of 14.3B. Regarding current trading prices, RIGL is priced at $29.37, while JAZZ trades at $227.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas JAZZ's P/E ratio is 2071.27. In terms of profitability, RIGL's ROE is +1.47%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RIGL is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check JAZZ's competition here
RIGL vs BBIO Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, RIGL is priced at $29.37, while BBIO trades at $65.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas BBIO's P/E ratio is -17.63. In terms of profitability, RIGL's ROE is +1.47%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RIGL is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check BBIO's competition here
RIGL vs KRTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RIGL is priced at $29.37, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RIGL's ROE is +1.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RIGL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check KRTX's competition here
RIGL vs IONS Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, RIGL is priced at $29.37, while IONS trades at $75.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas IONS's P/E ratio is -37.73. In terms of profitability, RIGL's ROE is +1.47%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RIGL is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check IONS's competition here
RIGL vs EXEL Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, EXEL has a market cap of 12.4B. Regarding current trading prices, RIGL is priced at $29.37, while EXEL trades at $49.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas EXEL's P/E ratio is 16.38. In terms of profitability, RIGL's ROE is +1.47%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RIGL is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check EXEL's competition here
RIGL vs MDGL Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, RIGL is priced at $29.37, while MDGL trades at $510.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas MDGL's P/E ratio is -37.88. In terms of profitability, RIGL's ROE is +1.47%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RIGL is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check MDGL's competition here
RIGL vs AXSM Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, AXSM has a market cap of 11.5B. Regarding current trading prices, RIGL is priced at $29.37, while AXSM trades at $224.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas AXSM's P/E ratio is -60.18. In terms of profitability, RIGL's ROE is +1.47%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RIGL is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check AXSM's competition here
RIGL vs RNAM Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RIGL is priced at $29.37, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RIGL's ROE is +1.47%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RIGL is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check RNAM's competition here
RIGL vs ARWR Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, RIGL is priced at $29.37, while ARWR trades at $79.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ARWR's P/E ratio is -34.82. In terms of profitability, RIGL's ROE is +1.47%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RIGL is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ARWR's competition here
RIGL vs BMRN Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, RIGL is priced at $29.37, while BMRN trades at $52.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas BMRN's P/E ratio is 38.04. In terms of profitability, RIGL's ROE is +1.47%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RIGL is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check BMRN's competition here
RIGL vs RXDX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RIGL is priced at $29.37, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RIGL's ROE is +1.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RIGL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check RXDX's competition here
RIGL vs CYTK Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CYTK has a market cap of 9.3B. Regarding current trading prices, RIGL is priced at $29.37, while CYTK trades at $74.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CYTK's P/E ratio is -10.92. In terms of profitability, RIGL's ROE is +1.47%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RIGL is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CYTK's competition here
RIGL vs KRYS Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, RIGL is priced at $29.37, while KRYS trades at $310.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas KRYS's P/E ratio is 41.49. In terms of profitability, RIGL's ROE is +1.47%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RIGL is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check KRYS's competition here
RIGL vs IMGN Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RIGL is priced at $29.37, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RIGL's ROE is +1.47%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RIGL is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check IMGN's competition here
RIGL vs IBRX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, RIGL is priced at $29.37, while IBRX trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas IBRX's P/E ratio is -10.02. In terms of profitability, RIGL's ROE is +1.47%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RIGL is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check IBRX's competition here
RIGL vs HALO Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, RIGL is priced at $29.37, while HALO trades at $70.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas HALO's P/E ratio is 27.71. In terms of profitability, RIGL's ROE is +1.47%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RIGL is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check HALO's competition here
RIGL vs BPMC Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RIGL is priced at $29.37, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RIGL's ROE is +1.47%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, RIGL is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check BPMC's competition here
RIGL vs CERE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RIGL is priced at $29.37, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CERE's P/E ratio is -16.47. In terms of profitability, RIGL's ROE is +1.47%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RIGL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CERE's competition here
RIGL vs ABVX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, RIGL is priced at $29.37, while ABVX trades at $121.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ABVX's P/E ratio is -21.43. In terms of profitability, RIGL's ROE is +1.47%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, RIGL is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ABVX's competition here
RIGL vs PCVX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, RIGL is priced at $29.37, while PCVX trades at $54.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas PCVX's P/E ratio is -7.84. In terms of profitability, RIGL's ROE is +1.47%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RIGL is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check PCVX's competition here
RIGL vs NUVL Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, RIGL is priced at $29.37, while NUVL trades at $102.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas NUVL's P/E ratio is -16.92. In terms of profitability, RIGL's ROE is +1.47%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RIGL is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check NUVL's competition here
RIGL vs MTSR Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RIGL is priced at $29.37, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RIGL's ROE is +1.47%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RIGL is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check MTSR's competition here
RIGL vs TECH Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, TECH has a market cap of 7.4B. Regarding current trading prices, RIGL is priced at $29.37, while TECH trades at $47.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas TECH's P/E ratio is 67.74. In terms of profitability, RIGL's ROE is +1.47%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RIGL is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check TECH's competition here
RIGL vs PRAX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, RIGL is priced at $29.37, while PRAX trades at $343.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas PRAX's P/E ratio is -25.65. In terms of profitability, RIGL's ROE is +1.47%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RIGL is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check PRAX's competition here
RIGL vs KYMR Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, RIGL is priced at $29.37, while KYMR trades at $83.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas KYMR's P/E ratio is -23.34. In terms of profitability, RIGL's ROE is +1.47%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RIGL is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check KYMR's competition here
RIGL vs MRUS Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RIGL is priced at $29.37, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RIGL's ROE is +1.47%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RIGL is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check MRUS's competition here
RIGL vs ACLX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RIGL is priced at $29.37, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RIGL's ROE is +1.47%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RIGL is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ACLX's competition here
RIGL vs RETA Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RIGL is priced at $29.37, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas RETA's P/E ratio is -66.29. In terms of profitability, RIGL's ROE is +1.47%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RIGL is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check RETA's competition here
RIGL vs TGTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, TGTX has a market cap of 6.5B. Regarding current trading prices, RIGL is priced at $29.37, while TGTX trades at $42.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas TGTX's P/E ratio is 14.87. In terms of profitability, RIGL's ROE is +1.47%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RIGL is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check TGTX's competition here
RIGL vs PTGX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, RIGL is priced at $29.37, while PTGX trades at $99.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas PTGX's P/E ratio is -55.22. In terms of profitability, RIGL's ROE is +1.47%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RIGL is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check PTGX's competition here
RIGL vs ALKS Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ALKS has a market cap of 6.4B. Regarding current trading prices, RIGL is priced at $29.37, while ALKS trades at $38.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ALKS's P/E ratio is 42.54. In terms of profitability, RIGL's ROE is +1.47%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RIGL is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ALKS's competition here
RIGL vs RYTM Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, RYTM has a market cap of 6.3B. Regarding current trading prices, RIGL is priced at $29.37, while RYTM trades at $91.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas RYTM's P/E ratio is -29.17. In terms of profitability, RIGL's ROE is +1.47%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RIGL is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check RYTM's competition here
RIGL vs PTCT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, PTCT has a market cap of 6.2B. Regarding current trading prices, RIGL is priced at $29.37, while PTCT trades at $75.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas PTCT's P/E ratio is -29.54. In terms of profitability, RIGL's ROE is +1.47%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RIGL is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check PTCT's competition here
RIGL vs BLTE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, RIGL is priced at $29.37, while BLTE trades at $155.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas BLTE's P/E ratio is -67.63. In terms of profitability, RIGL's ROE is +1.47%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, RIGL is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check BLTE's competition here
RIGL vs CNTA Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, RIGL is priced at $29.37, while CNTA trades at $39.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CNTA's P/E ratio is -22.25. In terms of profitability, RIGL's ROE is +1.47%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RIGL is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CNTA's competition here
RIGL vs CGON Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, RIGL is priced at $29.37, while CGON trades at $72.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CGON's P/E ratio is -30.80. In terms of profitability, RIGL's ROE is +1.47%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RIGL is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CGON's competition here
RIGL vs CELC Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CELC has a market cap of 6B. Regarding current trading prices, RIGL is priced at $29.37, while CELC trades at $124.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CELC's P/E ratio is -32.90. In terms of profitability, RIGL's ROE is +1.47%, compared to CELC's ROE of -2.03%. Regarding short-term risk, RIGL is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CELC's competition here
RIGL vs COGT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, RIGL is priced at $29.37, while COGT trades at $34.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas COGT's P/E ratio is -15.91. In terms of profitability, RIGL's ROE is +1.47%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RIGL is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check COGT's competition here
RIGL vs SRRK Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, RIGL is priced at $29.37, while SRRK trades at $49.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas SRRK's P/E ratio is -14.26. In terms of profitability, RIGL's ROE is +1.47%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RIGL is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check SRRK's competition here
RIGL vs IMVT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, IMVT has a market cap of 5.8B. Regarding current trading prices, RIGL is priced at $29.37, while IMVT trades at $28.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas IMVT's P/E ratio is -10.73. In terms of profitability, RIGL's ROE is +1.47%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, RIGL is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check IMVT's competition here
RIGL vs CDTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RIGL is priced at $29.37, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RIGL's ROE is +1.47%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RIGL is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CDTX's competition here
RIGL vs ABCM Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RIGL is priced at $29.37, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RIGL's ROE is +1.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RIGL is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ABCM's competition here
RIGL vs ISEE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RIGL is priced at $29.37, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RIGL's ROE is +1.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RIGL is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ISEE's competition here
RIGL vs CORT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, RIGL is priced at $29.37, while CORT trades at $51.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CORT's P/E ratio is 146.17. In terms of profitability, RIGL's ROE is +1.47%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RIGL is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CORT's competition here
RIGL vs MIRM Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, RIGL is priced at $29.37, while MIRM trades at $106.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas MIRM's P/E ratio is -7.86. In terms of profitability, RIGL's ROE is +1.47%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RIGL is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check MIRM's competition here
RIGL vs APLS Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RIGL is priced at $29.37, while APLS trades at $41.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas APLS's P/E ratio is 38.37. In terms of profitability, RIGL's ROE is +1.47%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RIGL is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check APLS's competition here
RIGL vs LEGN Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, RIGL is priced at $29.37, while LEGN trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas LEGN's P/E ratio is -17.44. In terms of profitability, RIGL's ROE is +1.47%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, RIGL is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RIGL.Check LEGN's competition here
RIGL vs FBIOX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, RIGL is priced at $29.37, while FBIOX trades at $25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RIGL's ROE is +1.47%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, RIGL is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check FBIOX's competition here
RIGL vs APGE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, RIGL is priced at $29.37, while APGE trades at $82.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas APGE's P/E ratio is -19.15. In terms of profitability, RIGL's ROE is +1.47%, compared to APGE's ROE of -0.24%. Regarding short-term risk, RIGL is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check APGE's competition here
RIGL vs CRSP Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, RIGL is priced at $29.37, while CRSP trades at $52.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CRSP's P/E ratio is -8.56. In terms of profitability, RIGL's ROE is +1.47%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RIGL is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CRSP's competition here
RIGL vs LQDA Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, LQDA has a market cap of 5B. Regarding current trading prices, RIGL is priced at $29.37, while LQDA trades at $56.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas LQDA's P/E ratio is 332.94. In terms of profitability, RIGL's ROE is +1.47%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RIGL is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RIGL.Check LQDA's competition here
RIGL vs TERN Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RIGL is priced at $29.37, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas TERN's P/E ratio is -51.41. In terms of profitability, RIGL's ROE is +1.47%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RIGL is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check TERN's competition here
RIGL vs CAI Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, RIGL is priced at $29.37, while CAI trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CAI's P/E ratio is -5.94. In terms of profitability, RIGL's ROE is +1.47%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RIGL is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CAI's competition here
RIGL vs FOLD Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RIGL is priced at $29.37, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RIGL's ROE is +1.47%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RIGL is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check FOLD's competition here
RIGL vs NAMS Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, NAMS has a market cap of 4.5B. Regarding current trading prices, RIGL is priced at $29.37, while NAMS trades at $38.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas NAMS's P/E ratio is -21.85. In terms of profitability, RIGL's ROE is +1.47%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RIGL is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check NAMS's competition here
RIGL vs SYRE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, RIGL is priced at $29.37, while SYRE trades at $75.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas SYRE's P/E ratio is -35.40. In terms of profitability, RIGL's ROE is +1.47%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RIGL is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check SYRE's competition here
RIGL vs AKRO Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RIGL is priced at $29.37, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RIGL's ROE is +1.47%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RIGL is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check AKRO's competition here
RIGL vs KNSA Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, KNSA has a market cap of 4.5B. Regarding current trading prices, RIGL is priced at $29.37, while KNSA trades at $59.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas KNSA's P/E ratio is 65.36. In terms of profitability, RIGL's ROE is +1.47%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, RIGL is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check KNSA's competition here
RIGL vs ALPN Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RIGL is priced at $29.37, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RIGL's ROE is +1.47%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RIGL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ALPN's competition here
RIGL vs LGND Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, RIGL is priced at $29.37, while LGND trades at $222.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas LGND's P/E ratio is 28.91. In terms of profitability, RIGL's ROE is +1.47%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RIGL is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check LGND's competition here
RIGL vs XENE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, RIGL is priced at $29.37, while XENE trades at $55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas XENE's P/E ratio is -11.70. In terms of profitability, RIGL's ROE is +1.47%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RIGL is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check XENE's competition here
RIGL vs MANE Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, RIGL is priced at $29.37, while MANE trades at $103.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas MANE's P/E ratio is -43.66. In terms of profitability, RIGL's ROE is +1.47%, compared to MANE's ROE of -0.76%. Regarding short-term risk, RIGL is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check MANE's competition here
RIGL vs OPT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RIGL is priced at $29.37, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas OPT's P/E ratio is -1.52. In terms of profitability, RIGL's ROE is +1.47%, compared to OPT's ROE of +0.88%. Regarding short-term risk, RIGL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check OPT's competition here
RIGL vs MRTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RIGL is priced at $29.37, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RIGL's ROE is +1.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RIGL is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check MRTX's competition here
RIGL vs TVTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, RIGL is priced at $29.37, while TVTX trades at $42.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas TVTX's P/E ratio is -85.68. In terms of profitability, RIGL's ROE is +1.47%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RIGL is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check TVTX's competition here
RIGL vs CRNX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, RIGL is priced at $29.37, while CRNX trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CRNX's P/E ratio is -7.18. In terms of profitability, RIGL's ROE is +1.47%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RIGL is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CRNX's competition here
RIGL vs CPRX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, RIGL is priced at $29.37, while CPRX trades at $31.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CPRX's P/E ratio is 18.54. In terms of profitability, RIGL's ROE is +1.47%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RIGL is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CPRX's competition here
RIGL vs RYZB Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RIGL is priced at $29.37, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RIGL's ROE is +1.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RIGL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check RYZB's competition here
RIGL vs CBAY Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RIGL is priced at $29.37, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RIGL's ROE is +1.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RIGL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check CBAY's competition here
RIGL vs ACAD Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, RIGL is priced at $29.37, while ACAD trades at $21.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ACAD's P/E ratio is 9.82. In terms of profitability, RIGL's ROE is +1.47%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RIGL is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ACAD's competition here
RIGL vs EWTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, RIGL is priced at $29.37, while EWTX trades at $34.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas EWTX's P/E ratio is -20.49. In terms of profitability, RIGL's ROE is +1.47%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RIGL is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check EWTX's competition here
RIGL vs VKTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, RIGL is priced at $29.37, while VKTX trades at $31.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas VKTX's P/E ratio is -7.55. In terms of profitability, RIGL's ROE is +1.47%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RIGL is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check VKTX's competition here
RIGL vs DNTH Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, RIGL is priced at $29.37, while DNTH trades at $86.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas DNTH's P/E ratio is -20.37. In terms of profitability, RIGL's ROE is +1.47%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RIGL is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check DNTH's competition here
RIGL vs SWTX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RIGL is priced at $29.37, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RIGL's ROE is +1.47%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, RIGL is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check SWTX's competition here
RIGL vs TLX Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, RIGL is priced at $29.37, while TLX trades at $10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas TLX's P/E ratio is -519.50. In terms of profitability, RIGL's ROE is +1.47%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RIGL is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check TLX's competition here
RIGL vs BEAM Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, RIGL is priced at $29.37, while BEAM trades at $31.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas BEAM's P/E ratio is -64.45. In terms of profitability, RIGL's ROE is +1.47%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, RIGL is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check BEAM's competition here
RIGL vs ERAS Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, RIGL is priced at $29.37, while ERAS trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas ERAS's P/E ratio is -23.59. In terms of profitability, RIGL's ROE is +1.47%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RIGL is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check ERAS's competition here
RIGL vs VCYT Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, RIGL is priced at $29.37, while VCYT trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas VCYT's P/E ratio is 36.63. In terms of profitability, RIGL's ROE is +1.47%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, RIGL is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check VCYT's competition here
RIGL vs NAMSW Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, NAMSW has a market cap of 3.1B. Regarding current trading prices, RIGL is priced at $29.37, while NAMSW trades at $27.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas NAMSW's P/E ratio is N/A. In terms of profitability, RIGL's ROE is +1.47%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, RIGL is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check NAMSW's competition here
RIGL vs DNLI Comparison May 2026
RIGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RIGL stands at 543.4M. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, RIGL is priced at $29.37, while DNLI trades at $19.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RIGL currently has a P/E ratio of 1.52, whereas DNLI's P/E ratio is -6.76. In terms of profitability, RIGL's ROE is +1.47%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RIGL is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for RIGL.Check DNLI's competition here